IRIS Accounts Production v25.1.3.33 03424640 Board of Directors 1.9.23 31.8.24 31.8.24 false true false false true false Ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh034246402023-08-31034246402024-08-31034246402023-09-012024-08-31034246402022-08-31034246402022-09-012023-08-31034246402023-08-3103424640ns15:EnglandWales2023-09-012024-08-3103424640ns14:PoundSterling2023-09-012024-08-3103424640ns10:Director12023-09-012024-08-3103424640ns10:PrivateLimitedCompanyLtd2023-09-012024-08-3103424640ns10:SmallEntities2023-09-012024-08-3103424640ns10:AuditExempt-NoAccountantsReport2023-09-012024-08-3103424640ns10:SmallCompaniesRegimeForDirectorsReport2023-09-012024-08-3103424640ns10:SmallCompaniesRegimeForAccounts2023-09-012024-08-3103424640ns10:FullAccounts2023-09-012024-08-3103424640ns10:OrdinaryShareClass12023-09-012024-08-3103424640ns10:Director22023-09-012024-08-3103424640ns10:RegisteredOffice2023-09-012024-08-3103424640ns5:CurrentFinancialInstruments2024-08-3103424640ns5:CurrentFinancialInstruments2023-08-3103424640ns5:Non-currentFinancialInstruments2024-08-3103424640ns5:Non-currentFinancialInstruments2023-08-3103424640ns5:ShareCapital2024-08-3103424640ns5:ShareCapital2023-08-3103424640ns5:CapitalRedemptionReserve2024-08-3103424640ns5:CapitalRedemptionReserve2023-08-3103424640ns5:RetainedEarningsAccumulatedLosses2024-08-3103424640ns5:RetainedEarningsAccumulatedLosses2023-08-3103424640ns5:LeaseholdImprovements2023-09-012024-08-3103424640ns5:FurnitureFittings2023-09-012024-08-3103424640ns5:MotorVehicles2023-09-012024-08-3103424640ns5:LeaseholdImprovements2023-08-3103424640ns5:FurnitureFittings2023-08-3103424640ns5:MotorVehicles2023-08-3103424640ns5:LeaseholdImprovements2024-08-3103424640ns5:FurnitureFittings2024-08-3103424640ns5:MotorVehicles2024-08-3103424640ns5:LeaseholdImprovements2023-08-3103424640ns5:FurnitureFittings2023-08-3103424640ns5:MotorVehicles2023-08-3103424640ns5:WithinOneYearns5:CurrentFinancialInstruments2024-08-3103424640ns5:WithinOneYearns5:CurrentFinancialInstruments2023-08-3103424640ns5:WithinOneYearns5:CurrentFinancialInstrumentsns5:HirePurchaseContracts2024-08-3103424640ns5:WithinOneYearns5:CurrentFinancialInstrumentsns5:HirePurchaseContracts2023-08-3103424640ns5:BetweenOneFiveYearsns5:HirePurchaseContracts2024-08-3103424640ns5:BetweenOneFiveYearsns5:HirePurchaseContracts2023-08-3103424640ns5:HirePurchaseContracts2024-08-3103424640ns5:HirePurchaseContracts2023-08-3103424640ns5:WithinOneYear2024-08-3103424640ns5:WithinOneYear2023-08-3103424640ns5:BetweenOneFiveYears2024-08-3103424640ns5:BetweenOneFiveYears2023-08-3103424640ns5:AllPeriods2024-08-3103424640ns5:AllPeriods2023-08-3103424640ns10:OrdinaryShareClass12024-08-31034246401ns10:Director12023-08-31034246401ns10:Director12022-08-31034246401ns10:Director12023-09-012024-08-31034246401ns10:Director12022-09-012023-08-31034246401ns10:Director12024-08-31034246401ns10:Director12023-08-3103424640ns10:Director222023-08-3103424640ns10:Director222022-08-3103424640ns10:Director222023-09-012024-08-3103424640ns10:Director222022-09-012023-08-3103424640ns10:Director222024-08-3103424640ns10:Director222023-08-31
REGISTERED NUMBER: 03424640 (England and Wales)




FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 AUGUST 2024

FOR

EPSILON PHARMASERVICES LIMITED

EPSILON PHARMASERVICES LIMITED (REGISTERED NUMBER: 03424640)






CONTENTS OF THE FINANCIAL STATEMENTS
for the year ended 31 August 2024




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


EPSILON PHARMASERVICES LIMITED

COMPANY INFORMATION
for the year ended 31 August 2024







DIRECTORS: A C Winship
A C G Steel





REGISTERED OFFICE: The Old Barn
Gibbet Hill
Shawell
Lutterworth
Leicestershire
LE17 6RB





REGISTERED NUMBER: 03424640 (England and Wales)





ACCOUNTANTS: LDP Luckmans
1110 Elliott Court
Coventry Business Park
Herald Avenue
Coventry
West Midlands
CV5 6UB

EPSILON PHARMASERVICES LIMITED (REGISTERED NUMBER: 03424640)

BALANCE SHEET
31 August 2024

2024 2023
Notes £    £    £   
FIXED ASSETS
Tangible assets 4 443,178 121,972

CURRENT ASSETS
Stocks 5 50,463 64,901
Debtors 6 1,886,443 1,402,765
Cash at bank and in hand 1,307,648 1,262,768
3,244,554 2,730,434
CREDITORS
Amounts falling due within one year 7 1,101,424 509,660
NET CURRENT ASSETS 2,143,130 2,220,774
TOTAL ASSETS LESS CURRENT
LIABILITIES

2,586,308

2,342,746

CREDITORS
Amounts falling due after more than one
year

8

(57,869

)

(17,134

)

PROVISIONS FOR LIABILITIES (39,136 ) (26,733 )
NET ASSETS 2,489,303 2,298,879

CAPITAL AND RESERVES
Called up share capital 11 8,000 8,000
Capital redemption reserve 4,000 4,000
Retained earnings 2,477,303 2,286,879
SHAREHOLDERS' FUNDS 2,489,303 2,298,879

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 August 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 August 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

EPSILON PHARMASERVICES LIMITED (REGISTERED NUMBER: 03424640)

BALANCE SHEET - continued
31 August 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 29 May 2025 and were signed on its behalf by:





A C Winship - Director


EPSILON PHARMASERVICES LIMITED (REGISTERED NUMBER: 03424640)

NOTES TO THE FINANCIAL STATEMENTS
for the year ended 31 August 2024

1. STATUTORY INFORMATION

Epsilon Pharmaservices Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).


2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

The Company's turnover is generated from design, project management and installation services to the pharmaceutical industry.
Sales are accounted for as long term contracts under the provisions of Section 23 FRS102. Contract costs and turnover are recognised by reference to the stage of completion at the balance sheet date.When it is probable that contract costs will exceed the total contract turnover, the expected loss is recognised as an expense immediately, with a corresponding provision.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Improvements to property - 10% on cost
Fixtures and fittings - 20% on cost
Motor vehicles - 25% on cost

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.
Long term contracts are stated at net cost less foreseeable losses less any applicable payments on account. The amount recorded as turnover in respect of long term contracts is ascertained by reference to the value of the work carried out to date. Attributable profit is recognised as the difference between recorded turnover and related costs.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Statement of Income and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.


EPSILON PHARMASERVICES LIMITED (REGISTERED NUMBER: 03424640)

NOTES TO THE FINANCIAL STATEMENTS - continued
for the year ended 31 August 2024

2. ACCOUNTING POLICIES - continued
Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Foreign currencies
Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

Debtors and creditors receivable/payable within one year
Debtors and creditors with no stated interest rate and receivable or payable within one year are recorded at transaction price. Any losses arising from impairment are recognised in the profit and loss account in other administrative expenses.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 13 (2023 - 13 ) .

EPSILON PHARMASERVICES LIMITED (REGISTERED NUMBER: 03424640)

NOTES TO THE FINANCIAL STATEMENTS - continued
for the year ended 31 August 2024

4. TANGIBLE FIXED ASSETS
Improvements Fixtures
to and Motor
property fittings vehicles Totals
£    £    £    £   
COST
At 1 September 2023 - 256,006 271,470 527,476
Additions 244,084 86,126 103,237 433,447
Disposals - (198,678 ) (64,293 ) (262,971 )
At 31 August 2024 244,084 143,454 310,414 697,952
DEPRECIATION
At 1 September 2023 - 242,633 162,871 405,504
Charge for year - 23,223 72,945 96,168
Eliminated on disposal - (198,678 ) (48,220 ) (246,898 )
At 31 August 2024 - 67,178 187,596 254,774
NET BOOK VALUE
At 31 August 2024 244,084 76,276 122,818 443,178
At 31 August 2023 - 13,373 108,599 121,972

5. STOCKS
2024 2023
£    £   
Stocks 15,653 15,917
Work-in-progress 34,810 48,984
50,463 64,901

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Trade debtors 821,944 500,791
Amounts recoverable on contract 98,529 245,837
Other debtors 965,970 656,137
1,886,443 1,402,765

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Hire purchase contracts (see note 9) 26,641 22,770
Payments on account 229,311 42,528
Trade creditors 167,572 247,627
Amounts owed to group undertakings 600,000 -
Taxation and social security 36,168 142,380
Other creditors 41,732 54,355
1,101,424 509,660

EPSILON PHARMASERVICES LIMITED (REGISTERED NUMBER: 03424640)

NOTES TO THE FINANCIAL STATEMENTS - continued
for the year ended 31 August 2024

8. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE
YEAR
2024 2023
£    £   
Hire purchase contracts (see note 9) 57,869 17,134

9. LEASING AGREEMENTS

Minimum lease payments fall due as follows:

Hire purchase contracts
2024 2023
£    £   
Net obligations repayable:
Within one year 26,641 22,770
Between one and five years 57,869 17,134
84,510 39,904

Non-cancellable operating leases
2024 2023
£    £   
Within one year 46,000 19,452
Between one and five years 115,000 105,548
161,000 125,000

10. SECURED DEBTS

The following secured debts are included within creditors:

2024 2023
£    £   
Hire purchase contracts 84,510 39,904

Hire purchase is secured upon the asset to which the debt relates.

11. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2024 2023
value: £    £   
8,000 Ordinary £1 8,000 8,000

EPSILON PHARMASERVICES LIMITED (REGISTERED NUMBER: 03424640)

NOTES TO THE FINANCIAL STATEMENTS - continued
for the year ended 31 August 2024

12. DIRECTORS' ADVANCES, CREDITS AND GUARANTEES

The following advances and credits to directors subsisted during the years ended 31 August 2024 and 31 August 2023:

2024 2023
£    £   
A C Winship
Balance outstanding at start of year 430,000 -
Amounts advanced 12,649 430,000
Amounts repaid (30,000 ) -
Amounts written off - -
Amounts waived - -
Balance outstanding at end of year 412,649 430,000

A C G Steel
Balance outstanding at start of year 30,000 -
Amounts advanced - 30,000
Amounts repaid (30,000 ) -
Amounts written off - -
Amounts waived - -
Balance outstanding at end of year - 30,000

Interest is charged on the loan to A Winship.

13. PARENT COMPANY

The parent company of the Entity from 14th November 2023 is Epsilon Pharmaservices Holdings Limited.